Mineralys Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Mineralys Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $30 Price Target
Goldman Sachs Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Cuts Target Price to $29
Stifel Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $45
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $26 to $45
Stifel Nicolaus Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Buy Rating for Mineralys Therapeutics Amid Strong Financials and Promising Lorundrostat Trials
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Durect (DRRX) and Globus Medical (GMED)
Mineralys Therapeutics Analyst Ratings
HC Wainwright & Co. Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30
Buy Rating Justified by Mineralys Therapeutics' Promising Hypertension and CKD Drug Lorundrostat
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)
Mineralys Therapeutics Analyst Ratings
Goldman Sachs Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30
Analysts Offer Insights on Healthcare Companies: Resmed (RMD), Mineralys Therapeutics, Inc. (MLYS) and Addus Homecare (ADUS)
Buy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic Developments
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX) and Mineralys Therapeutics, Inc. (MLYS)
Credit Suisse: Maintaining the Mineralys Therapeutics (MLYS.US) rating, adjusted from superior to market ratings, the target price was adjusted from $38.00 to $37.00.
Credit Suisse Maintains Outperform on Mineralys Therapeutics, Lowers Price Target to $37